Current status of developments in the field of respiratory syncytial virus vaccines
Respiratory syncytial virus (RSV) is the leading cause of upper respiratory tract infections in children and the elderly. The only specific treatment approved for RSV is the monoclonal antibody Palivizumab for passive immunoprophylaxis in high-risk infants. Sixty years after the virus was discovered...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Central Research Institute for Epidemiology
2025-05-01
|
| Series: | Журнал микробиологии, эпидемиологии и иммунобиологии |
| Subjects: | |
| Online Access: | https://microbiol.crie.ru/jour/article/viewFile/18831/1595 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|